Abstract
The purpose of this study was to investigate the effect of protein tyrosine phosphatase 1B (PTP1B) inhibitors and taurine on blood lipid profiles of the obese adolescent. Three week-old thirty-six male Sprague-Dawley rats were randomly assigned to six groups (high fat diet (HFD) group, HFD group; high fat diet + taurine group, HFD + taurine (TR) group; high fat diet + PTP1B inhibitor A (A) group, HF + A group; high fat diet + PTP1B inhibitor B, HF + B group; high fat diet + PTP1B inhibitor A + taurine group, HF + A + TR group; and high fat diet + PTP1B inhibitor B + taurine group, HF+B+TR group). The body weight of the HF+A and HF \ + A + TR groups were significantly reduced compared to those of the other groups, the exception being the HF + B + TR group. Serum triglyceride (TG), total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) levels of the HF + A + TR group were significantly reduced compared to those of the other groups. However, serum high density lipoprotein cholesterol (HDL-C) levels in HF + B + TR group was significantly reduced compared those of the HFD and HF + TR groups. Therefore, these results suggest a possible effect of PTP1B inhibitors and taurine on blood triglyceride, total cholesterol and low density lipoprotein cholesterol in the obese adolescent.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Reference
Ahn JH, Cho SY, Ha JD, Kang SK, Jung SH, Kim HM, Kim SS, Kim KR, Cheon HG, Yang SD, Choi JK(2003) Protein tyrosine phosphatase 1B inhibitors: catechols. Bull Korean Chem Soc 24:1505–1508
Balkan J, Öztezcan S, Hatipoglu A, Çevikbaş U, Aykaĉ-Toker G, Uysal M(2004) Effect of taurine treatment on the regression of existing atherosclerotic lesions in rabbits fed a high-cholesterol diet. Biosci Biotechnol Biochem 68:1035–1039
Bays HE(2004) Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obesity Research 12:384–387
Bence KK, Delidegovic M, Xue B, Gorgun CZ, Hotamisligil GS, Neel BG, Kahn BB(2006) Neuronal PTP1B regulates body weight, adiposity and leptin action. Nat Med 12:917–924
Bharatham K, Bharatham N, Leem KW(2007) Pharmacophore modeling for protein tyrosine phosphatase 1B inhibitors. Arch Pharm Res 30:533–542
Brøns C, Spohr C, Storgaard H, Dyerberg J, Vaag A(2004) Effect of taurine treatment on insulin secretion and action, and on serum lipid levels in overweight men with a genetic predisposition for type diabetes mellitus. Eur J Clin Nutr 58:1239–1247
Burke TR Jr, Zhang ZY(1998) Protein-tyrosine phosphatases: structure, mechanism, and inhibitor discovery. Biopolymers 47:225–241
Choi MJ, Kim JH, Chang KJ(2006) The effect of dietary taurine supplementation on plasma and liver lipid concentrations and free amino acid concentrations in rats fed a high-cholesterol diet. Adv Exp Med Biol 583:235-242
Dubé N, Tremblay ML(2005) Involvement of the small protein tyrosine phosphatase TC-PTP and PTP1B in signal transduction and diseases: from diabetes, obesity to cell cycle, and cancer. Biochim Biophys Acta 1754:108–117
Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6): 499–502
Ito T, Azuma J (2004) Taurine is a possible anti-atherosclerotic agent. Nippon Yakurigaku Zasshi 123(5):311–317
Kishida T, Miyazato S, Ogawa H, Ebihara K (2003) Taurine prevents hypercholesterolemia in ovariectomized rats fed corn oil but not in those fed coconut oil. J Nutr 133:2616–2621
Klaman LD, Boss O, Peroni OD, Kim JK, Martino JL, Zabolotny JM, Moghal N, Lubkin M, Kim YB, Sharpe AH, Stricker-Krongrad A, Shulman GI, Neel BG, Kahn BB (2000) Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol 20:5479–5489
Korner J, Aronne LJ (2003) The emerging science of body weight regulation and its impact on obesity treatment. J Clin Invest 111:565-570
Lund IK, Hansen JA, Andersen HS, Møller NPH, Billestrup N (2005) Mechanism of protein tyrosine phosphotase 1B-mediated inhibition of leptin signaling. J Mol Endocrinol 34:339-351
Obinata K, Maruyama T, Hayashi M, Watanabe T, Nittono H (1996) Effect of taurine on the fatty liver of children with simple obesity. Adv Exp Med Biol 403:607–613
Sethupathy S, Elanchezhiyan C, Vasudevan K, Rajagopal G (2002) Antiatherogenic effect of taurine in high fat diet fed rats. Indian J Exp Biol 40:1169–1172
Shrestha S, Bhattarai BR, Chang KJ, Lee KH, Cho H (2007) Methylenedisicylic acid derivatives: new PTP1B inhibitors that confer resistance to diet-induced obesity. Bioorg Med Chem Lett 17:2760–2764
Tsuboyama-Kasaoka N, Shozawa C, Sano K, Kamei Y, Kasaoka S, Hosokawa Y, Ezaki O (2007) Taurine (2-aminoethanesulfonic acid) deficiency creates a vicious circle promoting obesity. Endocrinology 147: 3276–3284
Zhang M, Bi LF, Fang JH, Su XL, Da GL, Kuwamori T, Kagamimori S (2004) Beneficial effects of taurine on serum lipids in overweight or obese non-diabetic subjects. Amino Acids 26:267-271
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this paper
Cite this paper
Cheong, S.H., Cho, H., Chang, K.J. (2009). Effect of PTP1B Inhibitors and Taurine on Blood Lipid Profiles in Adolescent Obesity. In: Azuma, J., Schaffer, S.W., Ito, T. (eds) Taurine 7. Advances in Experimental Medicine and Biology, vol 643. Springer, New York, NY. https://doi.org/10.1007/978-0-387-75681-3_39
Download citation
DOI: https://doi.org/10.1007/978-0-387-75681-3_39
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-75680-6
Online ISBN: 978-0-387-75681-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)